Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWG | ISIN: US76155X1000 | Ticker-Symbol: 42Z
Tradegate
06.06.25 | 16:36
36,200 Euro
+2,84 % +1,000
1-Jahres-Chart
REVOLUTION MEDICINES INC Chart 1 Jahr
5-Tage-Chart
REVOLUTION MEDICINES INC 5-Tage-Chart
RealtimeGeldBriefZeit
36,40037,00017:29
36,40037,00017:28

Aktuelle News zur REVOLUTION MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Revolution Medicines startet Phase-3-Studie für Lungenkrebs-Medikament5
14.05.Revolution Medicines begins phase 3 trial for lung cancer drug1
07.05.Revolution Medicines, Inc. - 10-Q, Quarterly Report2
07.05.Revolution Medicines GAAP EPS of -$1.13 misses by $0.033
REVOLUTION MEDICINES Aktie jetzt für 0€ handeln
07.05.Revolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress124Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell...
► Artikel lesen
30.04.Revolution Medicines, Inc.: Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 20253
28.04.Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?8
27.04.Revolution Medicines, Inc.: Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting7
01.04.Revolution Medicines, Inc.: Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting6
31.03.Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now5
26.02.Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress467Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout...
► Artikel lesen
26.02.Revolution Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Revolution Medicines, Inc. - 10-K, Annual Report-
26.02.Revolution Medicines, Inc. - 8-K, Current Report-
19.02.Revolution Medicines, Inc.: Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 202512
17.01.Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential11
02.12.24Revolution Medicines, Inc.: Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio234Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for...
► Artikel lesen
06.11.24Revolution Medicines, Inc.: Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress147Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805...
► Artikel lesen
25.10.24Revolution Medicines, Inc.: Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma480First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October...
► Artikel lesen
23.10.24Revolution Medicines, Inc.: Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma146Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1